Thus, the nasal spray delivery of dimeric or secretory IgA antibodies holds the potential to effectively block viral infection and enhance mucosal immunity against severe acute respiratory syndrome coronavirus 2. The gene discussed is CD79A; the disease is viral infectious disease.